Author:
Qiao Xinran,Gan Maoluo,Wang Chen,Liu Bin,Shang Yue,Li Yi,Chen Shuzhen
Abstract
Tetracenomycin X (Tcm X) has been reported to have antitumour activity in various cancers, but there have not been any studies on its activity with respect to lung cancer to date. Therefore, this study aims to investigate the anti-lung cancer activity of Tcm X. In this study, we found that tetracenomycin X showed antitumour activity in vivo and selectively inhibited the proliferation of lung cancer cells without influencing lung fibroblasts. In addition, apoptosis and autophagy did not contribute to the antitumour activity. Tetracenomycin X exerts antitumour activity through cell cycle arrest induced by the downregulation of cyclin D1. To explore the specific mechanism, we found that tetracenomycin X directly induced cyclin D1 proteasomal degradation and indirectly downregulated cyclin D1 via the activation of p38 and c-JUN proteins. All these findings were explored for the first time, which indicated that tetracenomycin X may be a powerful antimitotic class of anticancer drug candidates for the treatment of lung cancer in the future.
Subject
Drug Discovery,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Pharmaceutical Science
Reference20 articles.
1. Global cancer statistics, 2012
2. Lung cancer-A global perspective
3. Lung cancer screening: History, current perspectives, and future directions;Sharma;Arch. Med. Sci. AMS,2015
4. MicroRNA-202 induces cell cycle arrest and apoptosis in lung cancer cells through targeting cyclin D1;Jiang;Eur. Rev. Med. Pharm. Sci.,2016
5. 3-Demethoxy-3-ethoxy-tetracenomycin C.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献